PF-04691502 + letrozole

PF‑04691502 is an orally available small molecule that acts as a potent dual inhibitor of phosphatidylinositol 3 kinase (PI3K) and mammalian target of rapamycin (mTOR), targeting both TORC1 and TORC2 complexes. It was developed for the treatment of solid tumors, including breast cancer, by inhibiting the PI3K/mTOR signaling pathway which is involved in cell growth, survival, and resistance to therapy. Letrozole is a nonsteroidal aromatase inhibitor used primarily in postmenopausal women to treat hormone receptor-positive breast cancer by decreasing estrogen production. The combination has been investigated in clinical trials for early and advanced breast cancer[1][5][6].

Other names

2-amino-8-((1r,4r)-4-(2-hydroxyethoxy)cyclohexyl)-6-(6-methoxypyridin-3-yl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one